Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations to Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation allocations rather than operational financial performance.
Material Changes
On December 31, 2009, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of October 1, 2009, to December 31, 2009. The allocation price was set at £13.25 per Ordinary share and $42.40 per ADS. These allocations were formally notified to the Company and Directors on January 4, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Allocation Price: Ordinary shares were allocated at £13.25; ADSs at $42.40.
- Service Period: Awards cover the period from October 1, 2009, to December 31, 2009.
- Notification Date: The Company and Directors were informed of these allocations on January 4, 2010.
- Beneficiaries: Awards were distributed to ten Non-Executive Directors, including Sir Christopher Gent (2,547.17 Ordinary Shares) and Sir Crispin Davis (2,358.49 Ordinary Shares).